Taysha Gene Therapies Inc (TSHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Taysha Gene Therapies Inc (TSHA) has a cash flow conversion efficiency ratio of -0.110x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.17 Million) by net assets ($218.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Taysha Gene Therapies Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Taysha Gene Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Taysha Gene Therapies Inc for a breakdown of total debt and financial obligations.
Taysha Gene Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taysha Gene Therapies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RES.MINING UNSP.ADR/10
F:RSM0
|
N/A |
|
Advtech
JSE:ADH
|
0.311x |
|
Eit Environmental Development Group
SHE:300815
|
0.034x |
|
HannStar Board Corp
TW:5469
|
0.029x |
|
Guild Holdings Co
NYSE:GHLD
|
0.064x |
|
FAWER Automotive Parts Ltd Co
SHE:000030
|
0.029x |
|
JinkoSolar Holding Company Limited
NYSE:JKS
|
-0.268x |
|
Sunonwealth Electric Machine Industry Co Ltd
TW:2421
|
0.092x |
Annual Cash Flow Conversion Efficiency for Taysha Gene Therapies Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Taysha Gene Therapies Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see TSHA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.53 Million | $-81.22 Million | -1.136x | -16.55% |
| 2023-12-31 | $74.94 Million | $-73.02 Million | -0.974x | +98.95% |
| 2022-12-31 | $949.00K | $-88.39 Million | -93.140x | -7490.43% |
| 2021-12-31 | $95.38 Million | $-117.04 Million | -1.227x | -903.50% |
| 2020-12-31 | $251.30 Million | $-30.73 Million | -0.122x | +87.77% |
| 2019-12-31 | $-135.00K | $135.00K | -1.000x | -- |
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-11… Read more